Shares of Teva Pharmaceutical Industries Limited (TEVA) Sees Large Inflow of Net Money Flow

Teva Pharmaceutical Industries Limited (TEVA) : Fridays money flow indicated an uptick to downtick ratio was at 3.05. The total value of inflow transactions on upticks was $2.85 million, whereas, the total value of outflow trades on downticks was $0.94 million. The total money flow was $1.92 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $1.82 million. The total value of the trades done on upticks was $1.82 million. Teva Pharmaceutical Industries Limited (TEVA) was trading with a -0.33% change over previous days close. It fell $0.18 during the day and reached $54.45. The stock was 0.44% compared to the previous weeks close.


Teva Pharmaceutical Industries Limited (TEVA) : Currently there are 18 street experts covering Teva Pharmaceutical Industries Limited (TEVA) stock. The most bullish and bearish price target for the stock is $100 and $55 respectively for the short term. The average price target of all the analysts comes to $73.6. The estimated standard deviation from the target is $9.65.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): stock turned positive on Friday. Though the stock opened at $54.77, the bulls momentum made the stock top out at $54.96 level for the day. The stock recorded a low of $54.34 and closed the trading day at $54.73, in the green by 0.18%. The total traded volume for the day was 3,479,751. The stock had closed at $54.63 in the previous days trading.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.